Mindfulness Training Plus Oxytocin Effects on Smoking Behavior (MOXY)

Mindfulness Training Plus Oxytocin to Reduce Smoking and Craving Among Smokers in Withdrawal

The purpose of this study is to examine the effects of mindfulness training and a drug called oxytocin on smoking.

Study Overview

• Status: Terminated
• Conditions: Smoking; Smoking Cessation
• Intervention / Treatment: Drug: Oxytocin; Behavioral: Mindfulness; Drug: Saline Solution; Behavioral: Sham mindfulness

Detailed Description

Mindfulness training allows individuals to be present with their own emotions, thoughts, and bodily sensations without reactive judgment, and will be given in the form of daily audio recordings. Oxytocin is a naturally occurring hormone in the brain and throughout the body. It is also an FDA-approved drug to help induce labor in pregnant women. In this study, the use oxytocin is experimental and is in the form of a nasal spray.

• Study Type: Interventional
• Enrollment (Actual): 20
• Phase: Phase 2; Phase 3

Contacts and Locations

Study Locations

• United States
  • California
    • Los Angeles, California, United States, 90033
      • University of Southern California

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 40 years (Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Smoke at least 10 cigarettes per day for the past year

Exclusion Criteria:

• Current DSM-5 substance use disorder
• Any medial condition that would increase risk for study participation
• Women who are pregnant or nursing
• Current use of psychiatric medication for anxiety or mood disorders
• Planning to quit or reduce smoking in the next 30 days
• Current regular use of other nicotine-containing products
• Current mindfulness or mediation practice of greater than 5 minutes per day

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Factorial Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Mindfulness and intranasal oxytocin; Given oxytocin through intranasal administration and self-directed mindfulness training.	Drug: Oxytocin; A single 40 IU dose of Pitocin (oxytocin, USP; concentration = 10 IU/1 mL; PAR Pharmaceuticals, NY, USA) will be self-administered to each participant. Each 40 IU dose will be transferred into four, 1 ml intranasal atomizers and will be administered in four sprays to each nostril over the course of 15 minutes.; Behavioral: Mindfulness; Participants will be instructed to listen to and practice a 20-minute guided mediation each day for 7 days prior to the experimental session. The guided mindfulness practices will include body scan and seated stillness meditations.
Active Comparator: Mindfulness and placebo; Given sterile saline through intranasal adminstration and self-directed mindfulness training.	Behavioral: Mindfulness; Participants will be instructed to listen to and practice a 20-minute guided mediation each day for 7 days prior to the experimental session. The guided mindfulness practices will include body scan and seated stillness meditations.; Drug: Saline Solution; A single 40mL doses of sterile saline (0.9% provided by USC pharmacy) will be transferred into four, 1 ml intranasal atomizers and will be self-administered in four sprays to each nostril over the course of 15 minutes.
Sham Comparator: Sham mindfulness and placebo; Given sterile saline through intranasal adminstration and sham self-directed mindfulness training.	Drug: Saline Solution; A single 40mL doses of sterile saline (0.9% provided by USC pharmacy) will be transferred into four, 1 ml intranasal atomizers and will be self-administered in four sprays to each nostril over the course of 15 minutes.; Behavioral: Sham mindfulness; The mindfulness sham group will be required to listen to 20-minutes of Tedtalk podcasts each day that match the attention and time of the mindfulness group. Participants will be instructed to listen to two 10-minutes segments per day in succession between lab visits while in a seated posture.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Smoking Lapse Analogue Task (delay score)	This task measures ability to resist the temptation to initiate smoking under conditions in which it is advantageous to remain abstinent. The "delay score" is the number of minutes before participants begin smoking (0-50 min).	2 hours after nasal spray administration
Trier Social Stress Test	This test measures self-reported responses to stress in a lab setting over the course of 30 minutes through salivary cortisol and heart rate variability.	1 hour after nasal spray administration

Secondary Outcome Measures

Outcome Measure	Time Frame
Systolic blood pressure	Throughout study completion, an average of two weeks.
Diastolic blood pressure	Throughout study completion, an average of two weeks.
Heart rate	Throughout study completion, an average of two weeks.

Collaborators and Investigators

• Sponsor: University of Southern California
• Collaborators: MGM Foundation
• Investigators: Principal Investigator: Matthew Kirkpatrick, PhD, University of Southern California

Study record dates

Study Major Dates

• Study Start (Actual): October 10, 2018
• Primary Completion (Actual): December 31, 2023
• Study Completion (Actual): December 31, 2023

Study Registration Dates

• First Submitted: January 16, 2019
• First Submitted That Met QC Criteria: January 25, 2019
• First Posted (Actual): January 28, 2019

Study Record Updates

• Last Update Posted (Actual): June 14, 2024
• Last Update Submitted That Met QC Criteria: June 12, 2024
• Last Verified: June 1, 2024

More Information

Terms related to this study

• Keywords: Mindfulness; Oxytocin
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Reproductive Control Agents; Oxytocics; Oxytocin
• Other Study ID Numbers: HS-17-00972

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No